Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.59 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 5/20 | 0.43 |
| ▸ | CA2 | P00918 | 5/20 | 0.43 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | MPO | P05164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3507942 | 0.84 | IDO1 (0.57) | IDO1HSPA5KEAP1TSHRCYP2D6 | |
| SCHEMBL185874 | 0.83 | IDO1 (0.55) | IDO1HSPA5KEAP1TSHRCYP2D6 | |
| SCHEMBL185875 | 0.81 | IDO1 (0.53) | IDO1HSPA5KEAP1TSHRCYP2D6 | |
| SCHEMBL29152360 | 0.79 | IDO1 (0.52) | IDO1HSPA5KEAP1TSHRCYP2D6 | |
| SCHEMBL126999 | 0.78 | IDO1 (0.67) | IDO1HSPA5KEAP1TSHRCYP2D6 | |
| SCHEMBL497740 | 0.78 | IDO1 (0.50) | IDO1HSPA5KEAP1TSHRCYP2D6 | |
| SCHEMBL7101247 | 0.76 | IDO1 (0.64) | IDO1HSPA5KEAP1TSHRCYP2D6 | |
| SCHEMBL557812 | 0.74 | IDO1 (0.61) | IDO1HSPA5KEAP1TSHRCYP2D6 | |
| SCHEMBL11791488 | 0.74 | IDO1 (0.61) | IDO1HSPA5KEAP1TSHRCYP2D6 | |
| SCHEMBL14538248 | 0.74 | IDO1 (1.00) | IDO1HSPA5KEAP1TSHRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6025493-A | — | — | None | — | — | JP | disclosed |
| US-9156875-B2 | Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties | ADIUTIDE PHARMACEUTICALS GMBH (DE) | 2015-10-13 | — | — | US | disclosed |
| EP-2207787-B1 | IMMUNE STIMULATORY OLIGORIBONUCLEOTIDE ANALOGS CONTAINING MODIFIED OLIGOPHOSPHATE MOIETIES | ADIUTIDE PHARMACEUTICALS GMBH (DE) | 2014-11-12 | — | — | EP | disclosed |
| US-20130164333-A1 | IMMUNE STIMULATORY OLIGORIBONUCLEOTIDE ANALOGS CONTAINING MODIFIED OLIGOPHOSPHATE MOIETIES | ADIUTIDE PHARMACEUTICALS GMBH (DE) | 2013-06-27 | — | — | US | disclosed |
| US-8349812-B2 | Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties | ADIUTIDE PHARMACEUTICALS GMBH (DE) | 2013-01-08 | — | — | US | disclosed |
| US-20100260788-A1 | Immune Stimulatory Oligoribonucleotide Analogs Containing Modified Oligophosphate Moieties | DR. EUGEN UHLMANN (DE) | 2010-10-14 | — | — | US | disclosed |
| EP-2207787-A2 | IMMUNE STIMULATORY OLIGORIBONUCLEOTIDE ANALOGS CONTAINING MODIFIED OLIGOPHOSPHATE MOIETIES | Uhlmann, Eugen (DE) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009060281-A2 | IMMUNE STIMULATORY OLIGORIBONUCLEOTIDE ANALOGS CONTAINING MODIFIED OLIGOPHOSPHATE MOIETIES | COLEY PHARMACEUTICAL GMBH (DE) | 2009-05-14 | — | — | WO | disclosed |
| JP-H0625493-A | THERMALLY STABLE CHLORINATED RESIN COMPOSITION | AKISHIMA KAGAKU KOGYO KK | 1994-02-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100260788-A1 | Immune Stimulatory Oligoribonucleotide Analogs Containing Modified Oligophosphate Moieties | TLR3, TLR5, TLR9 | IDO1 250/4885HSPA5 2089/4885KEAP1 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.